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Appropriate medical decision-making in patients with 
keratinocyte skin cancer (KSC) can be challenging, es-
pecially in those with a limited life expectancy (LEx). 
Treatment should be beneficial for the individual pa-
tient, the risk of both over- and under-treatment should 
be carefully considered, and deviation from guideline 
recommendations may be necessary. In this study re-
trospective analysis was performed to determine the 
influence of age and comorbidity, both factors stron-
gly related to limited LEx, on KSC management in daily 
practice. After analysis of 401 patients it was found 
that management in patients with KSC is not influen-
ced, or is only minimally influenced, by high age and 
comorbidity. Better integration of aspects related to a 
limited LEx in KSC management might optimize care 
and prevent overtreatment. Future research on the ge-
neral prognostication, prediction of the patient burden 
caused by tumour and treatment, and time-to-benefit 
in KSC management is strongly recommended.
Key words: keratinocyte skin cancer; limited life expectancy; 
frail older adults; geriatric dermatology; skin cancer manage-
ment; clinical practice guideline.
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Dermatologists are increasingly likely to be confron-ted with older adults with multiple comorbidities 
who have keratinocyte skin cancer (KSC), considering: 
(i) the increasing incidence rates of KSC in general; (ii) 
the rising incidence rates of KSC with increasing age; 
(iii) and the ageing world population (1, 2). In general, 
the majority of KSC has a relatively low malignant 
potential compared with many other types of cancer. 
However, potential morbidity and mortality should not be 
underestimated (1). Adequate medical decision-making 
in patients with KSC requires physicians to be aware of 
several important aspects, including patient and tumour 
characteristics (e.g. tumour subtype, comorbidity, and 
life expectancy), treatment goals, and the availability 
of diagnostic and treatment options. Treatment should 
be beneficial for the individual patient, and the risks 
of both over- and under-treatment should be carefully 
weighed. Consequently, management decisions in pa-
tients with KSC may be challenging, especially in the 
growing population of frail older adults with a limited 
life expectancy (LEx) (3, 4). 
The main purpose of clinical practice guidelines 
(CPGs) is to assist physicians in medical decision-
making, based on the best evidence available, thereby 
optimizing healthcare (5). However, CPG recommen-
dations might not be applicable to every individual, and 
CPG guidance for older adult patients and patients with 
multiple comorbidities is limited (6–8). Therefore, pro-
perly reasoned deviation from CPG recommendations 
may be in the best interest of a patient and should be 
considered in some situations. 
Estimating a patient’s LEx is difficult. In addition to 
age, a patient’s LEx may be influenced by several factors, 
of which comorbidity is considered the strongest and 
best-studied predictor (9–13). It might be expected that 
a limited LEx and influencing factors might contribute 
to the extent of deviation from CPG in KSC, but little 
is known regarding these decisions from daily practice. 
Hence, the aim of this study was to determine the in-
fluence of high age and comorbidity on management in 
patients with KSC in daily clinical practice.
METHODS
Setting and patient selection
Patients with KSC seen in the outpatient dermatology department 
of Radboud University Medical Centre, Nijmegen, the Nether-
lands, were analysed retrospectively. Selection of histologically 
proven basal cell carcinomas (BCCs) or squamous cell carcinomas 
(SCCs) diagnosed in 2012 or 2013 took place using the national 
pathology database (Pathologisch-Anatomisch Landelijk Geauto-
matiseerd Archief; PALGA) combined with patient charts. Patients 
were sorted into 2 age groups (< 80 or ≥ 80 years), based on the 
United Nations (UN) age stratification (2) and the Dutch LEx data 
by Statistics Netherlands (mean residual LEx of 4.5 years at an 
age of 80 years) (14, 15). Since every lesion suspicious for KSC 
is histopathologically confirmed in our hospital, it is assumed 
that no cases were missed. In case multiple tumours per patient 
were found, only the first tumour was included. Exclusion criteria 
were: (i) tumours other than BCC or SCC (including basosqua-
mous carcinoma); (ii) non-cutaneous tumours (e.g. mucosal); 
(iii) patients using chronic immunosuppressive medication; (iv) 
patients having a genetic disorder resulting in an increased risk of 
developing KSC (e.g. basal cell naevus syndrome, oculocutaneous 
albinism, and epidermodysplasia verruciformis); (v) clinical trial 
subjects; and (vi) patients in whom diagnosis and/or treatment was 
not performed within our hospital. 
Impact of High Age and Comorbidity on Management Decisions and 
Adherence to Guidelines in Patients with Keratinocyte Skin Cancer 
Satish F. K. LUBEEK1, Celia A. J. MICHIELSENS1, Rinke J. BORGONJEN1, Ewald M. BRONKHORST2, Peter C. M. VAN DE 
KERKHOF1 and Marie-Jeanne P. GERRITSEN1 
1Department of Dermatology, and 2Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands
A
ct
aD
V
A
ct
aD
V
A
d
v
a
n
c
e
s 
in
 d
e
rm
a
to
lo
g
y
 a
n
d
 v
e
n
e
re
o
lo
g
y
A
c
ta
 D
e
rm
a
to
-V
e
n
e
re
o
lo
g
ic
a
S. F. K. Lubeek et al.826
www.medicaljournals.se/acta
Data collection and quality control
Data for all included patients were independently collected by 2 
data collectors (SL and CM) using a standardized form. Discre-
pancies between the 2 data collectors were discussed and, in case 
no consensus could be reached, a third author was consulted (RB 
or MJG). A pilot study of 20 patients was initially performed as 
a data-collection training (to test the standardized form, to dis-
cuss doubtful cases, and to increase inter-observer agreement). 
A data-collector manual was created to document all definitions 
and agreements. 
Patient and tumour characteristics
Several patient and tumour characteristics were collected (Table 
I). Comorbidity was classified using the Deyo adaptation of the 
Charlson Comorbidity Index (CCI; ICD-10 version), which is 
the most commonly used tool to assess comorbidity, validated in 
several populations. This includes assigning a weighted score to 
17 groups of comorbid conditions when present in a patient (re-
sulting in a score ranging from 0 to 30). Weights are based on their 
relative risk on 1-year mortality (12, 13, 16–18). When tumour 
characteristics were reported inconsistently, the pathology report 
after surgical excision overruled the biopsy report. 
Management decision
Data regarding management decisions 
and adherence to guidelines, including 
reasons for non-adherence, were collected. 
Adherence to guidelines was based on 
2 AUDIT-checklists for BCC and SCC, 
respectively (Appendices S1 and S21). The 
16-item checklist for BCC was based on a 
previously developed and tested checklist 
(19). The 21-item checklist used for SCC 
was newly developed using the same prin-
ciples as the BCC checklist. Both check-
lists included items related to risk factors, 
diagnosis, staging, treatment, prevention, 
and follow-up. All included items were 
directly based on recommendations from 
the Dutch guidelines (20, 21). Adherence 
to guidelines was calculated by dividing 
the number of items fulfilled by the total 
number of items. Only items applicable 
for that specific patient were included 
in the calculation (e.g. in case a tumour 
was treated solely with radiotherapy the 
items regarding surgical excision were 
not included). 
Statistical analysis
The primary outcome of this study was 
adherence to guidelines (which included 
data regarding management decisions). 
Age and comorbidity are the main factors 
of influence studied regarding adherence 
to guidelines. Interobserver agreement was 
measured using Cohen’s κ for each relevant 
variable. Since the amount of missing data 
was small, no imputation of missing data 
was performed and only the available data 
per variable was analysed. For a detailed 
description of the univariate and multivari-
able logistic regression models used in this 
study see Appendix S31. Statistical analysis 
was performed using the Statistical Package for Social Sciences 
(SPSS), version 22.0 (IBM Corporation, Armonk, NY, USA).
RESULTS
Patient and tumour characteristics
A total of 401 patients were included in the study, of 
which 128 patients were aged ≥ 80 years. Interobserver 
agreement was substantial to excellent for all variables 
(median κ=0,971; range 0.646–1.000). All discrepancies 
could be solved during consensus-meetings between 
the 2 data collectors. Comparison between the 2 age 
groups showed that more patients within the older age 
group had a positive history for KSC and a higher CCI. 
Furthermore, tumours within the older age group were 
more often SCC, less often superficial BCC, more often 
located within the head-and-neck area and had a larger 
Table I. Patient and tumour characteristics 
Characteristic
Overall 
population
(n = 401)
Patients aged 
< 80 years 
(n = 273)
Patients aged 
≥80 years 
(n = 128) p-value
Patient
Age, years, median (range)   71.0 (30–97) 64.0 (30–79) 83.0 (80–97) < 0.001*
Male sex, n (%) 203 (50.6) 133 (48.7) 70 (54.7) 0.265
Positive history for KSC, n (%)a 222 (55.5) 131 (48.0) 91 (71.7) < 0.001*
Charlson comorbidity index, median (range) 1 (0–7) 0 (0–7) 2 (0–7) < 0.001*
Tumour-related complaintsb, n (%):
Yes 138 (34.4) 96 (35.2) 42 (32.8) 0.897
No 235 (58.6) 158 (57.9) 77 (60.2)
Unknown 28 (7.0) 19 (7.0) 9 (7.0)
Tumour
Histopathological subtype, n (%):
SCC 75 (18.7) 34 (12.5) 41 (32.0) < 0.001*
Nodular BCC 81 (20.2) 59 (21.6) 22 (17.2)
Superficial BCC 89 (22.2) 77 (28.2) 12 (9.4)
Infiltrative BCC 47 (11.7) 30 (11.0) 17 (13.3)
Micronodular BCC 40 (10.0) 31 (11.4) 9 (7.0)
Mixed type BCC 69 (17.2) 42 (15.4) 27 (21.1)
Location, n (%):
Head-and-neck area 215 (53.6) 126 (46.2) 89 (69.5) < 0.001*
Trunk 121 (30.2) 101 (37.0) 20 (15.6)
Upper limbs 27 (6.7) 18 (6.6) 9 (7.0)
Lower limbs 38 (9.5) 28 (10.3) 10 (7.8)
High-risk location, n (%):
H-zonec 129 (39.6) 82 (34.3) 47 (54.0) 0.001*
Lip or eard 4 (5.3) 2 (5.9) 2 (4.9) 1.000
Largest diameter in mm, median (range)e 9.0 (2–45) 8.0 (2–30) 10.0 (2–45) 0.027*
Tumour depth in mm4, median (range)f 2.0 (1–9) 2.0 (1–8) 2.5 (1–9) 0.267
Degree of histological differentiationd, n (%):
Well-differentiated 26 (34.7) 17 (50.0) 9 (22.0) 0.029*
Moderately-differentiated 43 (57.3) 15 (44.1) 28 (68.3)
Poorly-differentiated 2 (2.7) 0 (0) 2 (4.9)
Perineural invasiond,g, n (%) 6 (8.5) 1 (3.2) 5 (12.5) 0.222
Vascular and/or lymphatic invasiond,g, n (%) 1 (1.4) 0 (0) 1 (2.5) NA
Previously treated (recurrence), n (%) 24 (6.0) 15 (5.5) 9 (7.0) 0.545
TNM-staged,h, n (%)
Stage I 58 (77.3) 28 (82.4) 30 (73.2) 0.344
Stage II or higher 17 (22.7) 6 (17.6) 11 (26.8)
a1 missing; bTumour-related complaints mentioned were bleeding, itch, pain and/or ulceration; cBasal cell 
carcinoma (BCC) only; d Squamous cell carcinoma (SCC) only; e33 missing; f2 missing: g4 missing. hStaging 
based on the classification of the American Joint Commission on Cancer (AJCC) tumor/node/metastasis (TNM) 
system (26); *p ≤ 0.05 (shown in bold). Values may not add up due to missing data and rounding.
KSC: keratinocyte skin cancer; NA: not applicable.
1https://www.medicaljournals.se/acta/content/abstract/10.2340/00015555-2670
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diameter. A full overview of patient and tumour charac-
teristics is given in Table I. 
Management decisions 
Univariate analysis. In both SCC and BCC, conventio-
nal surgical excision was the treatment option perfor-
med most frequently (Tables SI and SII1). Comparison 
between both age groups in BCC showed that Mohs 
micrographic surgery (MMS) was performed less often 
(8.4% vs. 1.1%, overall p = 0.004), and radiotherapy (RT) 
was performed more often in the older age group (2.5% 
vs. 10.3%, overall p = 0.004). In SCC, no differences 
regarding treatment options were found comparing both 
age groups. 
Multivariate analyses. Secondary multivariate logistic 
regression analyses were performed to study the ma-
nagement differences found in the univariate analysis 
in more detail. As the number of treatments with MMS 
and RT were performed in BCC was rather small (21 
and 15 times, respectively), a large logistic regression 
model was not possible. Hence, 3 consecutive analyses 
were performed for each treatment option, each with age 
and one important confounder (location, previous treat-
ment, and CCI, respectively). Inclusion of BCC subtype 
in the model was not possible due to: (i) the relatively 
low number of BCC treated by MMS and RT; and (ii) 
the extent of variance found in different BCC subtypes 
treated by both treatment options. MMS was less often 
performed in BCC in the older age group compared with 
the younger patients (1.1% vs. 8.4%; p = 0.019). This 
finding persisted after consecutive correction for pre-
vious treatment (primary vs. recurrent BCC (p = 0.042)) 
and location (within or without the H-zone; p = 0.014). 
After correction for CCI the model failed to show a 
statistical significant difference in treatment of BCC by 
MMS between the 2 age groups, although a trend could 
be seen (p = 0.056). The opposite was observed for RT 
in BCC, which was more frequently performed in the 
older patient group compared with the younger (10.3% 
vs. 2.5%; p = 0.003), also after consecutive correction 
for previous treatment (p = 0.007), location (p = 0.033) 
and CCI (p = 0.011). 
Adherence to guidelines
Univariate analyses. Overall adherence to guidelines was 
high (88% vs. 90% for SCC and BCC, respectively) and 
did not differ between the 2 age groups (p = 0.898 and 
p = 0.301, respectively), as also shown in Tables SI and 
SII1. When focusing more specifically on the individual 
guideline recommendations advice on appropriate sun 
protection was less frequently provided in the older age 
group with BCC (77.4% vs. 51.7%, p < 0.001), while 
the primary care physician was more frequently infor-
med about the diagnosis and management in the older 
age group with BCC (87.4% vs. 96.6%, p = 0.016). All 
other guideline recommendations showed no difference 
in adherence between both age groups. In 4.5% (n = 25) 
of the deviations from guideline recommendations, 
the reason was extractable from the patient chart. The 
most frequently mentioned reasons for deviation from 
guidelines were: (i) a limited LEx; (ii) severe impaired 
mobility; and (iii) patient’s refusal.
Multivariate analyses. Adherence to guidelines below 
90% was considered as “low” adherence to guidelines 
(cut-off based on approximate median). The multivariate 
logistic regression model for this dependent variable is 
presented in Table II. The results of this model show 
that adherence to guidelines is not influenced by age 
(odds ratio (OR) = 0.834; 95% confidence interval (95% 
CI) 0.508–1.371; p = 0.475) or comorbidity (OR 0.919; 
95% CI 0.764–1.106; p = 0.373), after correction for the 
other variables. Of the other variables in the model, the 
effect of tumour type is by far the most clear (p = 0.026). 
Much better adherence to guidelines in patients with a 
superficial BCC, as opposed to patients with a SCC, 
(OR 5.309; 95% CI 2.042–13.804; p = 0.001) was noted.
DISCUSSION
This study shows that management decisions in BCC 
are influenced by high age to some extent, while the 
influence of comorbidity seems only minimal to absent. 
Table II. Multivariate logistic regression model of the correlation 
of different factors in adherence to guidelines with at least 90% 
as dependent variable
Variable Odds ratio 95% CI p-value
Age (<80 vs. ≥80 years) 0.834 0.508–1.371 0.475
Charlson comorbidity index (0–30) 0.919 0.764–1.106 0.373
Previous treatment (yes vs. no) 0.608 0.241–1.536 0.293
Treatment method 0.754
Conventional SE Reference
Photodynamic therapy 0.985 0.371–2.616 0.976
Topical imiquimod 0.558 0.164–1.902 0.351
Mohs micrographic surgery 2.020 0.669–6.094 0.212
Radiotherapy 1.085 0.381–3.095 0.878
Other 0.867 0.049–15.208 0.922
Tumour type 0.026*
SCC Reference
Nodular BCC 1.950 0.878–4.331 0.101
Superficial BCC 5.309 2.042–13.804 0.001*
Infiltrative BCC 1.875 0.791–4.448 0.154
Micronodular BCC 1.419 0.577–3.489 0.445
Mixed type BCC 1.540 0.710–3.342 0.274
Location 0.227
Head-and-neck area Reference
Trunk 0.684 0.350–1.336 0.266
Upper limbs 0.563 0.215–1.477 0.243
Lower limbs 0.397 0.160–0.984 0.046*
Location (high vs. low risk)a 1.402 0.728–2.700 0.312
Complaints 0.280
No Reference
Yes 1.449 0.915–2.294 0.114
Unknown 1.045 0.452–2.419 0.918
aA basal cell carcinoma (BCC) located in the H-zone or a squamous cell carcinoma 
(SCC) located on an ear or lip. *p ≤ 0.05 (shown in bold).
CI: confidence interval; SE: surgical excision.
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Furthermore, high age and comorbidity did not have a 
significant influence on management decisions in SCC, 
or on overall guideline-adherence in both BCC and 
SCC. The possibility to draw direct conclusions from 
the results found in this study with respect to quality of 
care is limited and the definition of optimal skin cancer 
care remains open for discussion. One might expect de-
viation from regular treatment protocols and guideline 
recommendations in KSC to be more common among 
frail older adults with a limited LEx; however, this was 
not shown by the results of this study. 
Studies on the impact of high age and comorbidity 
on treatment decisions in KSC patients are scarce. Two 
studies from the USA showed that a limited LEx did 
not influence treatment decisions in patients with KSC, 
including treatment with MMS (22, 23). These studies 
show important agreement with our findings that high 
age and comorbidity do not have a significant influence 
on treatment choice in SCC and the decision not to treat 
KSC is rare. On the other hand, our finding that MMS 
is less frequently performed in patients ≥ 80 years with 
BCC, while RT is more frequently used in this popula-
tion, seems to contradict these studies, which might 
be explained by differences in healthcare systems and 
guidelines between countries.
It should be pointed out that medical decision-making 
solely based on age might be a pitfall, since age alone is 
just one factor influencing life expectancy and the popu-
lation of older adults is heterogeneous. For instance, on 
the one hand, MMS is a treatment option, which might 
lead to a significant patient burden and overtreatment in 
some (frail) older patients, especially in case a patient 
will not live long enough to benefit from this treatment 
(time-to-benefit principle) (22, 23). On the other hand, 
MMS is a suitable treatment option in some (less frail) 
older adults and exclusion solely based on age seems 
to be an insufficient selection method (24). We believe 
(more extensive) inclusion of patient characteristics 
related to frailty and a limited LEx in medical decision-
making in older adults optimizes KSC care. Examples 
of these characteristics are: comorbidity, cognition, 
and functional status. Clinicians may be stimulated to 
act on this in a greater extent through education, more 
cooperation with elderly care specialists, and further 
inclusion of these considerations within clinical practice 
guidelines (8). Furthermore, we believe that watchful 
waiting is a suitable alternative for treatment in some 
patients with an asymptomatic low-risk KSC, which 
should be considered more frequently in patients with 
a limited LEx. Instruments to determine (the extent of) 
frailty and a patient’s general prognosis can assist in these 
management decisions; however, currently these are not 
validated for patients with KSC (25). Consequently, since 
reliable and validated methods for general prognostica-
tion, prediction of the patient burden caused by tumour 
and treatment, and time-to-benefit data are lacking in 
current KSC literature, management decisions in daily 
practice might remain complex. We strongly recommend 
focussing future research on these aspects in order to 
provide guidance for clinicians. 
Study limitations
Generalization of the results in this single-centre study 
from one university hospital in the Netherlands should 
be performed with care, since population and manage-
ment differences can exist between different healthcare 
institutions and countries. Since patient records were 
retrospectively studied, non-reporting bias might have 
occurred, which could have influenced data on adherence 
to guidelines. However, it is unlikely that this potential 
non-reporting bias differed among the compared patient 
groups, and therefore its influence on the main outcomes 
in this study is expected to be limited.
Conclusion
In contradiction with our expectations, the present study 
shows that management in patients with KSC is not, or is 
only minimally, influenced by high age and comorbidity. 
We believe that better integration of aspects related to a 
limited LEx in KSC management might optimize care 
and prevent overtreatment. Future research on general 
prognostication, prediction of the patient burden caused 
by tumour and treatment, and time-to-benefit in KSC 
management is strongly recommended.
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